Clinical Trials Browser

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-05-29

MK-6482-043

Phase 3 Recruiting

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07489495 2026-05-29

LITESPARK-034

Phase 3 Recruiting

758 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04924075 2026-05-28

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07049926 2026-05-26

MK-3475-03C

Phase 1/2 Recruiting

140 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04846920 2026-05-22

MK-6482-018

Phase 1 Completed

29 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04626479 2026-05-18

MK-3475-03A

Phase 1/2 Active not recruiting

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT06428396 2026-05-18

LITESPARK-029

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT05239728 2026-05-15

MK-6482-022

Phase 3 Active not recruiting

1,800 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Phase 3 Active not recruiting

755 enrolled 28 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04626518 2026-05-06

KEYMAKER-U03

Phase 1/2 Active not recruiting

370 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04736706 2026-05-06

MK-6482-012

Phase 3 Active not recruiting

1,653 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04586231 2026-05-05

MK-6482-011

Phase 3 Active not recruiting

747 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03401788 2026-04-13

MK-6482-004

Phase 2 Active not recruiting

50 enrolled 1 FDA

von Hippel-Lindau Disease

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05468697 2026-01-23

MK-6482-024

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

80 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT05030506 2025-12-18

MK-6482-010

Phase 1 Active not recruiting

45 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

Phase 3 Active not recruiting

249 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02974738 2025-07-10

MK-6482-001

Phase 1 Active not recruiting

120 enrolled

CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Clinical Trials

LITESPARK-033

MK-6482-043

LITESPARK-034

MK-6482-015

MK-3475-03C

MK-6482-018

MK-3475-03A

LITESPARK-029

MK-6482-022

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

KEYMAKER-U03

MK-6482-012

MK-6482-011

MK-6482-004

KEYNOTE-365

MK-6482-024

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

MK-6482-010

MK-6482-001